Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland. - Patients willing to participate in the study and signed willing to sign a consent form Form (ICF). - Vaccination against N. meningitidis Who Should NOT Join This Trial: - Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP. - Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland. * Patients willing to participate in the study and signed Informed Consent Form (ICF). * Vaccination against N. meningitidis Exclusion Criteria: * Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP. * Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Treatments Being Tested

DRUG

Ravulizumab

Ravulizumab, concentrate for solution for infusion

Locations (14)

Research Site
Bydgoszcz, Poland
Research Site
Gdansk, Poland
Research Site
Katowice, Poland
Research Site
Katowice, Poland
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Poznan, Poland
Research Site
Poznan, Poland
Research Site
Szczecin, Poland
Research Site
Szczecin, Poland
Research Site
Warsaw, Poland
Research Site
Warsaw, Poland
Research Site
Wroclaw, Poland